A vaccine produced in partnership with Oxford University has faced a number of challenges in recent weeks
AstraZeneca’s COVID-19 vaccine may not be needed by the United States, even if it is approved by regulators, Anthony Fauci, chief infectious disease physician and director of the National Institute of Allergy and Infectious Diseases, told Reuters in an interview.
Fauci, who is the White House’s chief medical adviser, said the United States has made enough contracts with other manufacturers to vaccinate the entire population, and that perhaps that number of doses will be enough to re-vaccinate, which could take place this fall.
When asked if the United States would use the AstraZeneca vaccine, Fauci said, “It’s not decided yet. I believe that given the contractual relationship we have with a number of companies, we have enough vaccines to complete all of our tasks without resorting to AstraZeneca. ”
At the end of last year, the vaccine company and the University of Oxford released data from an earlier trial, which showed two different performance indicators at once, which was due to a dosing error. Then, in March, more than a dozen countries temporarily suspended the use of the AstraZeneca vaccine after it was linked to a rare bleeding disorder and related side effects.
Also in March, US health authorities said the data provided by the company did not provide a complete picture of the drug’s effectiveness. A few days later, AstraZeneca published results showing reduced, but still strong, efficacy for its vaccine.
Fauci said that “if we look at the amount (of doses) we are going to receive … from J&J, from Novavax, and from Moderna if we contract (with these companies) for more doses, it is likely that we can handle with any rapid growth (incidence of coronavirus). ” However, the doctor noted that he could not yet “unequivocally” answer this question.